In the context of a 10x Genomics webinar in September 2025, Explicyte presented an in vitro proof-of-concept using Xenium, demonstrating how the STAMP workflow (Pitino et al., Cell 2025) enables simultaneous extraction of cell phenotyping and gene expression data from PBMCs exposed to cancer immunotherapy, thereby capturing subtle shifts within rare cell populations.
Explicyte applied STAMP (Pitino et al. Cell 2025)—a sequencing-free, single-cell workflow on the 10x Xenium platform—to profile PBMCs under immunotherapy. In a single one-week run (16 samples simultaneously), STAMP delivers high-fidelity phenotyping of over 1 million cells alongside targeted gene-expression readouts at lower cost than scRNA-seq. Cross-validation with flow cytometry and bulk RNA-seq confirms STAMP’s accuracy, while its sensitivity reveals subtle therapy-induced shifts in rare immune subsets. This fast and cost-effective workflow opens new avenues for in vitro and ex vivo mechanistic studies.
